Azintuxizumab vedotin Withdrawn Phase 1 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02951117A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment